GSK plc
HealthcareNYSE:GSK · New York Stock Exchange
+$0.31 today
Vol 2.39M · Avg 4.07M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$32.8B of revenue converted into $5.8B of net income for the selected period. Gross margin is 72.8% and net margin is 17.9%, showing how much revenue survives after costs and taxes. EPS is $3.36, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.7B +4.1% | $31.4B +3.5% | $30.3B +3.4% | $29.3B +18.7% | $24.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.0B -0.3% | $9.0B +5.6% | $8.6B -10.4% | $9.6B +17.0% | $8.2B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $23.6B +5.9% | $22.3B +2.6% | $21.8B +10.1% | $19.8B +19.6% | $16.5B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.4% +1.2pp | 71.2% -0.6pp | 71.8% +4.3pp | 67.4% +0.5pp | 66.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.5B +17.6% | $6.4B +2.9% | $6.2B +13.4% | $5.5B +9.3% | $5.0B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $9.1B -17.5% | $11.0B +17.4% | $9.4B +12.1% | $8.4B +18.4% | $7.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $15.3B -16.4% | $18.3B +21.9% | $15.0B +12.6% | $13.3B +9.5% | $12.2B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.3B -9.3% | $2.6B +11.2% | $2.3B +6.8% | $2.1B +1.2% | $2.1B | $374.2M | $1.2B | $631.8M |
| EBITDA | $10.4B +56.0% | $6.7B -26.6% | $9.1B +5.6% | $8.6B +32.6% | $6.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 31.8% +10.6pp | 21.3% -8.7pp | 29.9% +0.6pp | 29.3% +3.1pp | 26.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $8.3B +107.4% | $4.0B -40.4% | $6.7B +4.8% | $6.4B +47.6% | $4.4B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 25.5% +12.7pp | 12.8% -9.4pp | 22.2% +0.3pp | 21.9% +4.3pp | 17.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $56.0M -16.9% | $67.4M +68.5% | $40.0M -37.8% | $64.3M +129.5% | $28.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $687.0M +4.5% | $657.6M -15.2% | $775.0M -9.4% | $855.5M +9.1% | $784.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$937.0M -72.2% | -$544.0M +20.1% | -$681.0M +15.4% | -$805.0M -6.2% | -$758.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $7.4B +112.9% | $3.5B -42.7% | $6.1B +7.7% | $5.6B +56.4% | $3.6B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 22.7% +11.6pp | 11.1% -8.9pp | 20.0% +0.8pp | 19.2% +4.6pp | 14.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.1B +111.4% | $526.0M -30.4% | $756.0M +6.9% | $707.0M +751.8% | $83.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $5.7B +122.0% | $2.6B -47.7% | $4.9B -67.1% | $15.0B +241.1% | $4.4B | $4.9B | $4.8B | $4.7B |
| Net Margin | 17.5% +9.3pp | 8.2% -8.0pp | 16.2% -34.8pp | 51.0% +33.2pp | 17.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $6 +347.6% | $1 -48.4% | $2 -67.2% | $7 +171.5% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $6 +348.4% | $1 -48.3% | $2 -67.2% | $7 +171.1% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.0B -50.3% | $2.0B +0.6% | $2.0B +0.6% | $2.0B +25.7% | $1.6B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.0B -50.3% | $2.1B +0.8% | $2.1B +0.7% | $2.0B +26.0% | $1.6B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.95B
Bristol-Myers Squibb Company
NYSE:BMY
$116.55B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.69B
Sanofi
NASDAQ:SNY
$106.46B
McKesson Corporation
NYSE:MCK
$94.83B
Elevance Health Inc.
NYSE:ELV
$87.28B
HCA Healthcare, Inc.
NYSE:HCA
$85.76B
Cigna Corporation
NYSE:CI
$78.85B
Zoetis Inc.
NYSE:ZTS
$33.64B
Bristol-Myers Squibb Company Ce
CELG-RI
$250.97M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GSK generate?
GSK plc (GSK) reported $32.67B of revenue in fiscal 2025.
Is GSK profitable?
GSK plc (GSK) reported $5.72B of net income, with a net margin of 17.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.